GET DAILY SIGNALSPhathom Pharmaceuticals (PHAT) Hits Key Milestones in Q3 Earnings Transition
Key Takeaways
- Phathom Pharmaceuticals reported third-quarter 2026 net revenue of $84.7 million, up 71% year over year and 14% sequentially.
- Non-GAAP earnings per share (EPS) came in at $0.04, while the GAAP net loss narrowed to $13.9 million (about $0.16 per share).
- The company delivered its second consecutive quarter of positive operating profit (excluding stock-based compensation) and positive cash from operations.
- Phathom reaffirmed full-year 2026 revenue guidance of $310 million to $325 million.
- Roughly 380,000 VOQUEZNA prescriptions were filled in Q3, pushing the cumulative total past 2 million filled prescriptions through mid-October.
- Gross margin landed near 78%, modestly below the roughly 80% target due to one-time charges.
- For more context on this ticker, explore Phathom Pharmaceuticals' Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
- Explore Trending AI Robots to discover AI-driven trading ideas and market signals.
Earnings Context and Why It Matters
Phathom Pharmaceuticals' third-quarter results mark an important milestone in the company's transition from a cash-burning biotech launch story to a commercially self-sustaining gastrointestinal (GI) franchise. The quarter's 71% revenue growth, combined with a second straight period of operating profitability and positive operating cash flow, signals that the VOQUEZNA franchise is scaling toward durable profitability. For investors, this report matters because it tests whether management's GI-focused sales strategy and expense discipline can convert strong prescription demand into sustained bottom-line improvement. With full-year guidance reaffirmed, the results offer a clearer picture of the company's trajectory heading into 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, PHAT reported net revenue of $84.7 million, a 71% increase from $49.5 million a year earlier and a 14% sequential gain. Approximately 380,000 VOQUEZNA prescriptions were filled during the quarter, including about 248,000 covered prescriptions and roughly 132,000 cash-pay prescriptions.
On a GAAP basis, the net loss narrowed to $13.9 million, or $0.16 per share, compared with a $30.0 million loss in the prior-year quarter. On a non-GAAP basis, the company posted EPS of $0.04, reflecting the removal of non-cash items such as stock-based compensation and certain interest charges. Revenue came in slightly below some consensus estimates, while non-GAAP EPS modestly beat expectations.
Operating profit, excluding stock-based compensation, reached about $5.8 million, and cash generated from operations was roughly $2.1 million. Cash operating expenses totaled about $60.5 million. Gross margin was approximately 78%, below the company's roughly 80% guidance, primarily due to one-time charges in cost of revenues. Phathom ended the quarter with $184.6 million in cash and cash equivalents and reaffirmed full-year 2026 revenue guidance of $310 million to $325 million.
Market Reaction and Investor Sentiment
Investor reaction to Phathom's third-quarter results leaned positive, with shares trading higher in early activity following the announcement as the market focused on the company's revenue growth and sustained profitability milestone rather than the slight revenue miss versus consensus. The reaffirmed full-year revenue guidance and commentary pointing toward continued operating profitability into the fourth quarter provided a supportive backdrop for sentiment. However, the stock has faced broader pressure over the trailing twelve months, and investor attention remains divided between the encouraging commercial momentum and lingering questions about gross-margin consistency, one-time cost items, and the pace of the company's path to durable positive cash flow in 2027.
Forward Outlook and Key Factors to Monitor
Looking ahead, Phathom's reaffirmed full-year 2026 revenue guidance of $310 million to $325 million suggests a meaningful fourth-quarter step-up is required, making prescription trends and covered-volume growth a critical near-term metric to watch. Management expects the full-year gross-to-net discount to land toward the lower end of its 55%–59% range, which could support revenue recognition if channel mix remains favorable.
On the cost side, investors should monitor whether gross margin returns toward the roughly 80% target now that the third quarter's one-time charges are behind the company. Cash operating expenses, guided at $235 million to $245 million excluding stock-based compensation, are tracking toward the lower end of that range, reinforcing the path to profitability.
Key catalysts ahead include continued growth in covered prescriptions, the outcome of clinical programs such as the eosinophilic esophagitis (EoE) and as-needed studies, and the company's progress toward its stated goal of durable positive cash flow in 2027. Changes to cash covenant requirements beginning in late 2027 also bear monitoring, though Phathom's current cash balance remains comfortably above its near-term requirements. From what I see, these elements will be worth tracking closely in the months ahead.
Exploring AI Trading Bots for Strategy Ideas
In my own analysis, I frequently use Tickeron's AI Trading Bots to test how earnings-driven momentum might play out across different market scenarios. This personal workflow helps me evaluate potential risk-reward profiles based on real-time signals and historical patterns, offering a practical layer to complement fundamental review without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PHAT's Indicator enters downward trend
The Aroon Indicator for PHAT entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 229 similar instances where the Aroon Indicator formed such a pattern. In 203 of the 229 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHAT as a result. In 57 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for PHAT turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 37 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PHAT's RSI Indicator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 62 cases where PHAT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +5.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAT advanced for three days, in 244 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PHAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.349) is normal, around the industry mean (3.154). P/E Ratio (-4.592) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (2.511) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. PHAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders
Industry Biotechnology
Advertisement